References
- Prum BE, Rosenberg LF, Gedde SJ, et al. Primary open-angle glaucoma preferred practice pattern® guidelines. Ophthalmology. 2016;123(1):P41–P111. doi:10.1016/j.ophtha.2015.10.053
- Harasymowycz P, Birt C, Gooi P, et al. Medical management of glaucoma in the 21st century from a Canadian perspective. J Ophthalmol. 2016;2016:6509809.
- Teus MA, Arranz-Marquez E. Prostaglandin F2α analogues in glaucoma management. Expert Review of Ophthalmology. 2008;3(2):203–209. doi:10.1586/17469899.3.2.203
- Li T, Lindsley K, Rouse B, et al. Comparative effectiveness of first-line medications for primary open-angle glaucoma: a systematic review and network meta-analysis. Ophthalmology. 2016;123(1):129–140. doi:10.1016/j.ophtha.2015.09.005
- Takagi Y, Nakajima T, Shimazaki A, et al. Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug. Experimental Eye Research. 2004;78(4):767–776. doi:10.1016/j.exer.2003.12.007
- SANTEN. SAFLUTAN 15 micrograms/mL eye drops, solution, in single-dose container - Summary of Product Characteristics (SmPC) - (eMC): Santen UK Limited. Available from: https://www.medicines.org.uk/emc/product/5115/smpc. Accessed December 18, 2018.
- Traverso CE, Ropo A, Papadia M, Uusitalo H. A phase II study on the duration and stability of the intraocular pressure-lowering effect and tolerability of Tafluprost compared with latanoprost. J Ocul Pharmacol Ther. 2010;26(1):97–104. doi:10.1089/jop.2009.0066
- Ge J, Li X, Sun X, He X, Zhang H. [Randomized parallel group study of 0.0015% tafluprost ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension (comparison with 0.005% latanoprost ophthalmic solution)]. Zhonghua Yan Ke Za Zhi. 2015;51(2):95–102. [Article in Chinese]
- Uusitalo H, Pillunat LE, Ropo A. Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study. Acta Ophthalmologica. 2010;88(1):12–19. doi:10.1111/j.1755-3768.2010.01862.x
- Siguan-Bell CS, Chansangpetch S, Perez CI, et al. Anterior segment parameters of Filipino-Americans compared to Chinese-Americans and Caucasian Americans using anterior segment optical coherence tomography. Transl Vis Sci Technol. 2019;8(2):11. doi:10.1167/tvst.8.2.11
- Sáles CS, Lee RY, Agadzi AK, Hee MR, Singh K, Lin SC. Open-angle glaucoma in Filipino and white Americans: a comparative study. J Glaucoma. 2014;23(4):246–253. doi:10.1097/IJG.0b013e318279b3e2
- Kuwayama Y, Nomura A. Prospective observational post-marketing study of tafluprost for glaucoma and ocular hypertension: short-term efficacy and safety. Adv Ther. 2014;31(4):461–471. doi:10.1007/s12325-014-0109-9
- Kuwayama Y, Hashimoto M, Kakegawa R, Nomura A, Shimada F. Prospective observational post-marketing study of tafluprost for glaucoma and ocular hypertension: effectiveness and treatment persistence. Adv Ther. 2017;34(6):1411–1425. doi:10.1007/s12325-017-0549-0
- Inoue K, Setogawa A, Tomita G. Nonresponders to prostaglandin analogs among normal-tension glaucoma patients. J Ocul Pharmacol Ther. 2016;32:90–96. doi:10.1089/jop.2015.0086
- Ikeda Y, Mori K, Tada K, Ueno M, Kinoshita S, Sotozono C. Comparison study of intraocular pressure reduction efficacy and safety between latanoprost and tafluprost in Japanese with normal-tension glaucoma. Clin Ophthalmol. 2016;10:1633–1637. doi:10.2147/OPTH.S108213